Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLC

Boston Common Asset Management LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,076 shares of the biopharmaceutical company’s stock after selling 3,296 shares during the period. Regeneron Pharmaceuticals accounts for about 0.8% of Boston Common Asset Management LLC’s investment portfolio, making the stock its 28th largest position. Boston Common Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $30,566,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of REGN. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $339,594,000. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the period. Finally, Swedbank AB acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $129,257,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 1.3 %

Regeneron Pharmaceuticals stock opened at $999.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market capitalization of $110.13 billion, a PE ratio of 26.46, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. The firm has a 50 day simple moving average of $1,121.23 and a 200-day simple moving average of $1,038.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.82 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. Royal Bank of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. TD Cowen upped their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $1,119.00.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.